Janux Therapeutics, Inc. (JANX) · Nov 5, 2026 · Earnings

Janux earnings beat as JANX013 enters the clinic

Beat — EPS -$0.34 vs ~-$0.47 consensus; revenue $9.29M vs ~$8.03M

Janux’s third-quarter earnings beat consensus and its pipeline advanced, but the bigger read now rests on JANX011 clinical data due November 9.

Janux remains a cash-rich, clinical-stage biotech building three immune-therapy platforms—TRACTr, TRACIr and ARM—with JANX007 as its lead prostate-cancer program and JANX011 as its first autoimmune-focused ARM candidate. The prior quarter had already set expectations for continued JANX007/JANX014 enrollment, JANX011 progress and JANX013 entering the clinic in the second half of 2026.

The quarter beat the modest financial bar. Collaboration revenue was $9.29 million versus a published consensus of roughly $8.03 million, while diluted loss per share was $0.34 versus an expected loss of about $0.47. The beat is real, but it is not the core investment case: Janux has no commercial product, and the revenue is collaboration-related rather than evidence of a scaled drug business.

Q3 2026Q3 2025Consensus
Collaboration revenue (Statements of Operations)$9.29M$10.00M$8.03M
Diluted EPS (Statements of Operations)$(0.34)$(0.39)$(0.47)
R&D expense (Statements of Operations)$30.6M$34.6M
Net loss (Statements of Operations)$21.6M$24.3M
Cash, equivalents and short-term investments (Financial Results)$945.7M$966.6M

The pipeline advanced, but mostly along the expected path. Janux dosed the first patient in the JANX013-plus-JANX007 Phase 1 study, while JANX007 and JANX014 continued enrolling in mCRPC. That converts the previously projected JANX013 start into a completed milestone, but it is still an early safety-stage event, not clinical proof of efficacy. 〔0〕

JANX011 is now the decisive near-term information event. The company has scheduled initial healthy-volunteer data for November 9, giving investors the first human read on whether its ARM design can produce deep B-cell depletion without excessive cytokine release. Until that update arrives, the filing advances the story operationally but does not yet validate the platform clinically.

Funding remains a strength, not a new surprise. Janux ended September with $945.7 million in cash, cash equivalents and short-term investments, down modestly from $966.6 million at year-end, leaving substantial resources to run several early-stage programs.

Bottom line: Janux delivered a clean quarterly beat and hit an expected pipeline milestone, making this modestly better than the standing setup. The filing matters less for the financials than for setting up the November 9 JANX011 data read, which is where the platform story faces its first meaningful clinical test.

What to watch next

JANX011 healthy-volunteer data webcast, November 9

Original filing on SEC EDGAR

More Janux Therapeutics, Inc. news

Janux earnings beat as JANX013 enters the clinic | JANX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.